Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30667167 | 0.94 | OPRM1 (0.38) | TDP1KDM4EOPRM1OPRK1OPRL1 | |
| SCHEMBL20434687 | 0.94 | L3MBTL3 (0.39) | TDP1KDM4EOPRM1OPRK1OPRL1 | |
| SCHEMBL19575067 | 0.88 | CYP2D6 (0.41) | TDP1KDM4EMAN2B1L3MBTL3L3MBTL1 | |
| SCHEMBL24210964 | 0.86 | SLC18A3 (0.40) | TDP1KDM4EOPRM1OPRK1OPRL1 | |
| SCHEMBL13931061 | 0.78 | HTR2C (0.40) | KDM4EOPRM1OPRK1OPRL1KMT2A | |
| SCHEMBL21508973 | 0.71 | MAN2B1 (0.39) | MAN2B1L3MBTL3L3MBTL1CYP2D6MEN1 | |
| SCHEMBL22853869 | 0.70 | CYP2D6 (0.36) | TDP1KDM4EMAN2B1CYP2D6MEN1 | |
| SCHEMBL20676120 | 0.69 | SLC18A3 (0.36) | TDP1KDM4EL3MBTL3L3MBTL1CYP2D6 | |
| SCHEMBL8900517 | 0.69 | OPRM1 (0.31) | OPRM1OPRK1OPRL1MEN1KMT2A | |
| SCHEMBL14197762 | 0.69 | ALDH1A1 (0.32) | KDM4EOPRM1OPRK1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10384950-B1 | Synthesis of molecular sieve SSZ-35 | CHEVRON U.S.A. INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3046875-B1 | METHOD FOR PREPARING ZEOLITE SSZ-35 | CHEVRON USA INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3046874-A1 | METHOD FOR PREPARING ZEOLITE SSZ-35 | Chevron U.S.A. Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-3046875-A1 | METHOD FOR PREPARING ZEOLITE SSZ-35 | Chevron U.S.A. Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9206052-B2 | Method for preparing zeolite SSZ-35 | CHEVRON U.S.A. INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8999288-B1 | Method for preparing zeolite SSZ-35 | CHEVRON U.S.A. INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150078991-A1 | METHOD FOR PREPARING ZEOLITE SSZ-35..test eDAN | CHEVRON U.S.A. INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150078990-A1 | METHOD FOR PREPARING ZEOLITE SSZ-35 | CHEVRON U.S.A. INC. | 2015-03-19 | — | — | US | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1994007863-A9 | OCTAHYDRONAPHTHOQUINOLIZINES, AND METHODS OF MAKING AND USING THEREOF | — | 1994-06-09 | — | — | WO | disclosed |
| WO-1994007863-A1 | OCTAHYDRONAPHTHOQUINOLIZINES, AND METHODS OF MAKING AND USING THEREOF | NEW YORK UNIVERSITY (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5298509-A | Octahydronaphthoquinolizines, and methods of making and using thereof | NEW YORK UNIVERSITY (US) | 1994-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | TDP1 2208/4885KDM4E 600/4885OPRM1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.